Etanercept (trade name Enbrel) is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile rheumatoid arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems.
| Attributes | Values |
|---|---|
| rdfs:comment |
|
| foaf:depiction | |
| ATC prefix |
|
| ATC suffix |
|
| Bioavailability |
|
| CAS number |
|
| DrugBank |
|
| FDA UNII code |
|
| thumbnail | |
| is product of |